Select Publications

Journal articles

Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID, 2021, 'ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)', BJU International, vol. 128, pp. 642 - 651, http://dx.doi.org/10.1111/bju.15491

Pathmanandavel S; Crumbaker M; Yam AO; Nguyen A; Rofe C; Hovey E; Gedye C; Kwan EM; Hauser C; Azad AA; Eu P; Martin AJ; Joshua AM; Emmett L, 2021, '177Lutetium PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castrate-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial.', J Nucl Med, http://dx.doi.org/10.2967/jnumed.121.262552

Kwan EM; Fettke H; Crumbaker M; Docanto MM; To SQ; Bukczynska P; Mant A; Ng N; Foroughi S; Graham LJK; Haynes AM; Azer S; Lim LE; Segelov E; Mahon K; Davis ID; Parente P; Pezaro C; Todenhöfer T; Sathianathen N; Hauser C; Horvath LG; Joshua AM; Azad AA, 2021, 'Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer', Translational Andrology and Urology, vol. 10, pp. 1688 - 1699, http://dx.doi.org/10.21037/tau-20-1444

Arasaratnam M; Balakrishnar B; Crumbaker M; Turner S; Hayden AJ; Brooks A; Patel MI; Lau H; Woo H; Bariol S; Gurney H, 2021, 'Patterns of care and outcomes of men with germ cell tumors in a high-volume Australian center', Asia-Pacific Journal of Clinical Oncology, http://dx.doi.org/10.1111/ajco.13548

Chan DL; Pavlakis N; Crumbaker M; Lawrence B; Barber C; Price TJ; Michael M; Oberg K, 2021, 'Vigilance for carcinoid heart disease is still required in the era of somatostatin analogues: Lessons from a case series', Asia-Pacific Journal of Clinical Oncology, http://dx.doi.org/10.1111/ajco.13577

Crumbaker M; Pathmanandavel S; Yam AO; Nguyen A; Ho B; Chan L; Ende JA; Rofe C; Kongrak K; Kwan EM; Azad AA; Sharma S; Pugh TJ; Danesh A; Keane J; Eu P; Joshua AM; Emmett L, 2021, 'Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN).', Eur Urol Oncol, vol. 4, pp. 963 - 970, http://dx.doi.org/10.1016/j.euo.2020.07.002

Bhatnagar A; McKay MJ; Arasaratnam M; Crumbaker M; Gurney H; Molloy MP, 2020, 'Evaluating bioanalytical capabilities of paper spray ionization for abiraterone drug quantification in patient plasma', Journal of Mass Spectrometry, vol. 55, pp. e4584, http://dx.doi.org/10.1002/jms.4584

Emmett L; Pathmanandavel S; Crumbaker M; Rofe C; Yam AOW; Ho B; Chan WL; Sharma S; Keane J; Hickey AJ; Fullard K; Kongrak K; Ratnayake L; Violet JA; Azad A; Eu P; Nguyen A; Joshua AM, 2020, 'Updated results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination 177Lu PSMA 617 and idronoxil in men with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial).', Journal of Clinical Oncology, vol. 38, pp. 5557 - 5557, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.5557

Crumbaker M; Chan EKF; Gong T; Corcoran N; Jaratlerdsiri W; Lyons RJ; Haynes AM; Kulidjian AA; Kalsbeek AMF; Petersen DC; Stricker PD; Jamieson CAM; Croucher PI; Hovens CM; Joshua AM; Hayes VM, 2020, 'The impact of whole genome data on therapeutic decision‐making in metastatic prostate cancer: A retrospective analysis', Cancers, vol. 12, http://dx.doi.org/10.3390/cancers12051178

Emmett L; Pathmanandavel S; Nguyen A; Crumbaker M; Yam AOW; Chan WL; Fullard K; Ho B; Azad A; Joshua AM, 2020, 'Results of a phase I/II prospective dose-escalation trial evaluating safety and efficacy of combination 177LuPSMA-617 and NOX66 in men with mCRPC post androgen signalling inhibition and two lines of taxane chemotherapy (LuPIN trial).', Journal of Clinical Oncology, vol. 38, pp. 120 - 120, http://dx.doi.org/10.1200/jco.2020.38.6_suppl.120

Quah GT; Espinoza D; Arasaratnam M; Crumbaker M; Balakrishnar B; Brooks A; Lau H; Patel M; Bariol S; Gurney H, 2020, '212P Stage I non-seminoma testicular cancer: Adjuvant management and outcomes', Annals of Oncology, vol. 31, pp. S1323 - S1323, http://dx.doi.org/10.1016/j.annonc.2020.10.223

Quah GT; Espinoza D; Crumbaker M; Balakrishnar B; Arasaratnam M; Bariol S; Brooks A; Lau H; Patel M; Gurney H, 2020, '213P Stage I seminoma testicular cancer: Predictors of relapse and outcomes for adjuvant carboplatin vs active surveillance', Annals of Oncology, vol. 31, pp. S1323 - S1323, http://dx.doi.org/10.1016/j.annonc.2020.10.224

Bhatnagar A; McKay MJ; Thaysen-Andersen M; Arasaratnam M; Crumbaker M; Gurney H; Molloy MP, 2019, 'Bioanalytical evaluation of dried plasma spots for monitoring of abiraterone and ∆(4)-abiraterone from cancer patients', Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 1126-1127, http://dx.doi.org/10.1016/j.jchromb.2019.121741

Crumbaker M; Wong J; Joshua AM; Spigelman AD, 2019, 'Outcomes of universal germline testing for men with prostate cancer in an Australian tertiary center', Asia-Pacific Journal of Clinical Oncology, vol. 15, pp. 257 - 261, http://dx.doi.org/10.1111/ajco.13148

Arasaratnam M; Crumbaker M; Bhatnagar A; McKay MJ; Molloy MP; Gurney H, 2019, 'Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer', Cancer Chemotherapy and Pharmacology, vol. 84, pp. 139 - 146, http://dx.doi.org/10.1007/s00280-019-03862-x

Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM, 2019, 'Results of a Prospective Phase 2 Pilot Trial of 177 Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression', Clinical Genitourinary Cancer, vol. 17, pp. 15 - 22, http://dx.doi.org/10.1016/j.clgc.2018.09.014

Crumbaker M; Emmett L; Horvath LG; Joshua AM, 2019, 'Exceptional response to 177lutetium prostate-specific membrane antigen in prostate cancer harboring DNA repair defects', JCO Precision Oncology, vol. 3, pp. 1 - 5, http://dx.doi.org/10.1200/PO.18.00237

Emmett L; Yin C; Crumbaker M; Hruby G; Kneebone A; Epstein R; Nguyen Q; Hickey A; Ihsheish N; O'Neill G; Horvath L; Chalasani V; Stricker P; Joshua AM, 2019, 'Rapid modulation of PSMA expression by androgen deprivation: Serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade', Journal of Nuclear Medicine, vol. 60, pp. 950 - 954, http://dx.doi.org/10.2967/jnumed.118.223099

Bhatnagar A; McKay MJ; Crumbaker M; Ahire K; Karuso P; Gurney H; Molloy MP, 2018, 'Quantitation of the anticancer drug abiraterone and its metabolite Δ(4)-abiraterone in human plasma using high-resolution mass spectrometry', Journal of Pharmaceutical and Biomedical Analysis, vol. 154, pp. 66 - 74, http://dx.doi.org/10.1016/j.jpba.2018.03.012

Arasaratnam M; Balakrishnar B; Crumbaker M; Turner S; Hayden A; Brooks A; Patel M; Gurney H, 2018, 'Patterns of care and outcome of germ cell tumours (GCT) in an Australian high-volume centre.', JOURNAL OF CLINICAL ONCOLOGY, vol. 36, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.e16534

Crumbaker M; Savdie R; Joshua AM, 2018, 'Refining the Assessment and Implications of AR-V7 in Castrate-resistant Prostate Cancer', European Urology, vol. 73, pp. 736 - 737, http://dx.doi.org/10.1016/j.eururo.2017.11.005

Crumbaker M; Guminski A; Gurney H; Sabanathan D; Wong S; Pavlakis N, 2018, 'Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia', Asia-Pacific Journal of Clinical Oncology, vol. 14, pp. e45 - e49, http://dx.doi.org/10.1111/ajco.12686

Crumbaker M; Gurney H, 2017, 'Dose considerations for anti-cancer drugs in metastatic prostate cancer', Prostate, vol. 77, pp. 1199 - 1204, http://dx.doi.org/10.1002/pros.23378

Crumbaker M; Khoja L; Joshua AM, 2017, 'AR signaling and the PI3K pathway in prostate cancer', Cancers, vol. 9, http://dx.doi.org/10.3390/cancers9040034

Mersiades A; Crumbaker M; Gao B; Nagrial A; Hui R, 2017, 'P3.02c-033 Patterns of Progression and Management of Acquired Resistance to Anti-PD-1 Antibodies in Advanced Non-Small Cell Lung Cancer', Journal of Thoracic Oncology, vol. 12, pp. S1293 - S1293, http://dx.doi.org/10.1016/j.jtho.2016.11.1828

Crumbaker M; Carlino M; Hui R; Mersiades A; Gurney H; Todd J; Gao B; Nagrial A, 2016, '471P Baseline full blood count parameters as predictors of response to PD-1 inhibition in advanced NSCLC', Annals of Oncology, vol. 27, pp. ix151 - ix151, http://dx.doi.org/10.1016/s0923-7534(21)00629-3

Crumbaker M; Carlino M; Hui R; Mersiades A; Gurney H; Todd J; Gao B; Nagrial A, 2016, '471P Baseline full blood count parameters as predictors of response to PD-1 inhibition in advanced NSCLC', Annals of Oncology, vol. 27, http://dx.doi.org/10.1093/annonc/mdw594.035

Chan D; McLachlan JM; Crumbaker M; Marx GM, 2015, 'Pretreatment neutrophil/lymphocyte ratio (NLR) prior to steroids as a prognostic factor in metastatic castrate refractory prostate cancer (mCRPC) patients treated with taxanes.', Journal of Clinical Oncology, vol. 33, pp. 273 - 273, http://dx.doi.org/10.1200/jco.2015.33.7_suppl.273

McLachlan JM; Chan DL; Crumbaker MA; Marx GM, 2015, 'Neutrophil-lymphocyte ratio prior to steroids as a prognostic marker in men with metastatic castration-resistant prostate cancer', Cancer Treatment Communications, vol. 4, pp. 81 - 85, http://dx.doi.org/10.1016/j.ctrc.2015.06.001


Back to profile page